# GeneQuine Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genequine-biotherapeutics

- Industry: Biotechnology
- Headquarters: Hamburg, Germany
- Website: www.genequine.com
- Total disclosed funding: $6.4M
- Latest round: Series A (Oct 22, 2020)
- Investors on record: 5

## About

Based in Hamburg, Germany, and founded in 2012, GeneQuine Biotherapeutics GmbH develops gene therapy-based drugs for the treatment of musculoskeletal diseases. Osteoarthritis is a joint disorder in humans and animals such as dogs and horses. The company founded by Killian Guse, PhD, and Stanislav Plutlzkl, PhD. In November 2012, GeneQuine Biotherapeutics GmbH invested seed funding from High-Tech Gründerfonds and Innovationsstarter Fonds Hamburg.

The company’s line of products; GQ2-201 is a gene therapy for the treatment of osteoarthritis in horses. GQ-202 a gene therapy treatment for osteoarthritis in dogs. While GQ-203 is a gene transfer vector for the treatment of osteoarthritis in humans. The company also provides GQ-301, GQ-302, and GQ-303 a gene therapy drugs for osteoarthritis of horses, dos, and humans.

GeneQuine Biotherapeutics GmbH plans to expand the gene therapy vector platform and to grow the company’s operations. The company also plans to develop new gene therapy for the treatment of intervertebral disc degeneration.

## Funding rounds

- Series A, Oct 22, 2020, $6.4M — High-Tech Gruenderfonds, Pacira Pharmaceuticals, Inc., Noshaq, SAMUM Vermögensverwaltungs GmbH
- Seed, Nov 12, 2012 — High-Tech Gruenderfonds, Innovationsstarter Fonds Hamburg
- Seed, Oct 30, 2012 — High-Tech Gruenderfonds, Innovationsstarter Fonds Hamburg

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed, Series A
- Innovationsstarter Fonds Hamburg (https://capitalatlas.ai/funds/innovationsstarter-fonds-hamburg) — Seed
- Pacira Pharmaceuticals, Inc. — Series A
- Noshaq (https://capitalatlas.ai/funds/noshaq) — Series A
- SAMUM Vermögensverwaltungs GmbH — Series A